Crossmark

Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5

Published Online: 2021-01-28

Authors

Marques, Gustavo Lenci

Hayashi, Shirley

Bjällmark, Anna

Larsson, Matilda

Riella, Miguel

Olandoski, Marcia

Lindholm, Bengt

Nascimento, Marcelo Mazza
License Information

Text and Data Mining valid from 2021-01-28

Version of Record valid from 2021-01-28
More Information

Article History

Received: 18 April 2020

Accepted: 14 January 2021

First Online: 28 January 2021

Competing interests

: Bengt Lindholm is employed by Baxter Healthcare. None of the other authors report any competing interests.

Document is current